4 Triple Negative Breast Cancer Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Triple Negative Breast Cancer Studies in San Francisco

NCT06393374Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TP...

San Francisco, CAPHASE31,530 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

San Francisco, CAPHASE31,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05377996Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors...

San Francisco, CAPHASE1360 participantsDay One Biopharmaceuticals, Inc.

View Study Details

NCT04434040Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulatin...

San Francisco, CAPHASE240 participantsDana-Farber Cancer Institute

View Study Details

About Triple Negative Breast Cancer Clinical Trials in San Francisco

Triple-negative breast cancer (TNBC) lacks estrogen receptors, progesterone receptors, and excess HER2 protein, limiting targeted treatment options. It accounts for about 10-15% of breast cancers and tends to be more aggressive. Active research focuses on immunotherapy and novel drug combinations.

There are currently 4 triple negative breast cancer clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 2,930 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Day One Biopharmaceuticals, Inc., Dana-Farber Cancer Institute. Clinical trial participation is free and participants receive study-related medical care at no cost.

Triple Negative Breast Cancer Clinical Trials in San Francisco — FAQ

Are there triple negative breast cancer clinical trials in San Francisco?

Yes, there are 4 triple negative breast cancer clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What triple negative breast cancer treatments are being tested?

The 4 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for triple negative breast cancer.

Data updated October 19, 2026 from ClinicalTrials.gov